Literature DB >> 11160735

Infectivity-enhancing antibodies to Ebola virus glycoprotein.

A Takada1, S Watanabe, K Okazaki, H Kida, Y Kawaoka.   

Abstract

Ebola virus causes severe hemorrhagic fever in primates, resulting in mortality rates of up to 100%, yet there are no satisfactory biologic explanations for this extreme virulence. Here we show that antisera produced by DNA immunization with a plasmid encoding the surface glycoprotein (GP) of the Zaire strain of Ebola virus enhances the infectivity of vesicular stomatitis virus pseudotyped with the GP. Substantially weaker enhancement was observed with antiserum to the GP of the Reston strain, which is much less pathogenic in humans than the Ebola Zaire and Sudan viruses. The enhancing activity was abolished by heat but was increased in the presence of complement system inhibitors, suggesting that heat-labile factors other than the complement system are required for this effect. We also generated an anti-Zaire GP monoclonal antibody that enhanced viral infectivity and another that neutralized it, indicating the presence of distinct epitopes for these properties. Our findings suggest that antibody-dependent enhancement of infectivity may account for the extreme virulence of the virus. They also raise issues about the development of Ebola virus vaccines and the use of passive prophylaxis or therapy with Ebola virus GP antibodies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160735      PMCID: PMC114815          DOI: 10.1128/JVI.75.5.2324-2330.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

Review 1.  DNA immunization: mechanistic studies.

Authors:  J L Whitton; F Rodriguez; J Zhang; D E Hassett
Journal:  Vaccine       Date:  1999-03-26       Impact factor: 3.641

2.  Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function.

Authors:  R J Wool-Lewis; P Bates
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 3.  Processing of the Ebola virus glycoprotein.

Authors:  V E Volchkov
Journal:  Curr Top Microbiol Immunol       Date:  1999       Impact factor: 4.291

Review 4.  Filovirus diseases.

Authors:  C J Peters; A S Khan
Journal:  Curr Top Microbiol Immunol       Date:  1999       Impact factor: 4.291

5.  Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins.

Authors:  Z Yang; R Delgado; L Xu; R F Todd; E G Nabel; A Sanchez; G J Nabel
Journal:  Science       Date:  1998-02-13       Impact factor: 47.728

6.  Processing of the Ebola virus glycoprotein by the proprotein convertase furin.

Authors:  V E Volchkov; H Feldmann; V A Volchkova; H D Klenk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

Review 7.  Enhancing antibodies in HIV infection.

Authors:  G Füst
Journal:  Parasitology       Date:  1997       Impact factor: 3.234

8.  A system for functional analysis of Ebola virus glycoprotein.

Authors:  A Takada; C Robison; H Goto; A Sanchez; K G Murti; M A Whitt; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

9.  Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines.

Authors:  R J Wool-Lewis; P Bates
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

10.  DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.

Authors:  L Vanderzanden; M Bray; D Fuller; T Roberts; D Custer; K Spik; P Jahrling; J Huggins; A Schmaljohn; C Schmaljohn
Journal:  Virology       Date:  1998-06-20       Impact factor: 3.616

View more
  48 in total

1.  Functional mapping of the nucleoprotein of Ebola virus.

Authors:  Shinji Watanabe; Takeshi Noda; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

2.  Antibody-dependent enhancement of Marburg virus infection.

Authors:  Eri Nakayama; Daisuke Tomabechi; Keita Matsuno; Noriko Kishida; Reiko Yoshida; Heinz Feldmann; Ayato Takada
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

3.  Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.

Authors:  Darryl Falzarano; Friederike Feldmann; Allen Grolla; Anders Leung; Hideki Ebihara; James E Strong; Andrea Marzi; Ayato Takada; Shane Jones; Jason Gren; Joan Geisbert; Steven M Jones; Thomas W Geisbert; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

4.  Interaction between TIM-1 and NPC1 Is Important for Cellular Entry of Ebola Virus.

Authors:  Makoto Kuroda; Daisuke Fujikura; Asuka Nanbo; Andrea Marzi; Osamu Noyori; Masahiro Kajihara; Junki Maruyama; Keita Matsuno; Hiroko Miyamoto; Reiko Yoshida; Heinz Feldmann; Ayato Takada
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

5.  Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.

Authors:  Anne-Laure Favier; Evelyne Gout; Olivier Reynard; Olivier Ferraris; Jean-Philippe Kleman; Viktor Volchkov; Christophe Peyrefitte; Nicole M Thielens
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

6.  Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.

Authors:  Natalia A Kuzmina; Patrick Younan; Pavlo Gilchuk; Rodrigo I Santos; Andrew I Flyak; Philipp A Ilinykh; Kai Huang; Ndongala M Lubaki; Palaniappan Ramanathan; James E Crowe; Alexander Bukreyev
Journal:  Cell Rep       Date:  2018-08-14       Impact factor: 9.423

7.  Replication-deficient ebolavirus as a vaccine candidate.

Authors:  Peter Halfmann; Hideki Ebihara; Andrea Marzi; Yasuko Hatta; Shinji Watanabe; M Suresh; Gabriele Neumann; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

8.  Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels.

Authors:  Atsushi Yamanaka; Saori Kosugi; Eiji Konishi
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

9.  VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice.

Authors:  Sven Enterlein; Kelly L Warfield; Dana L Swenson; David A Stein; Jeffery L Smith; C Scott Gamble; Andrew D Kroeker; Patrick L Iversen; Sina Bavari; Elke Mühlberger
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  Analysis of linear B-cell epitopes of the nucleoprotein of ebola virus that distinguish ebola virus subtypes.

Authors:  Masahiro Niikura; Tetsuro Ikegami; Masayuki Saijo; Takeshi Kurata; Ichiro Kurane; Shigeru Morikawa
Journal:  Clin Diagn Lab Immunol       Date:  2003-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.